Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case-control study

Diabetes Care

Volumn 29, Issue 5, 2006, Pages 1096-1101

  Lecube, Albert ^a   Hernández, Cristina ^a   Genescà, Joan ^a   Simó, Rafael ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CYTOKINE; GLUCAGON; INSULIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOOD INTAKE; GLUCOSE TOLERANCE TEST; HEPATITIS C; HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; LIVER FIBROSIS; MALE; PATHOGENESIS;

EID: 33746366223     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc05-2509     Document Type: Article

References (40)

1. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL: Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 133:592-599, 2000
2. Wang CS, Wang ST, Yao WJ, Chang TT, Chou P: Community-based study of hepatitis C virus infection and type 2 diabetes: an association affected by age and hepatitis severity status. Am J Epidemiol 158:1154-1160, 2003
3. Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, Guo L, Jacob S, Regenstein FG, Zimmerman R, Everhart JE, Wasserfall C, Maclaren NK, Perrillo RP: Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29:328-333, 1999
4. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL: Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Hepatology 3: 1554, 2001
5. Lecube A, Hernández C, Genescà J, Esteban JI, Jardí R, Simó R: High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury. Diabetes Care 27:1171-1175, 2004
6. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, Corpas R, Cruz M, Grande L, Vazquez L, Munoz-De-Rueda P, Lopez-Serrano P, Gila A, Gutierrez ML, Perez C, Ruiz-Extremera A, Suarez E, Castillo J: Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128:636-641, 2005
7. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, Moriya K, Koike K: Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 126:840-848, 2004
8. Knobler H, Zhornicky T, Sandler A, Haran N, Ashur Y, Schattner A: Tumor necrosis factor-α-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol 98:2751-2756, 2003
9. Elsammak M, Refai W, Elsawaf A, Abdel-Fattah I, Elatti A, Ghazal A: Elevated serum tumor necrosis alpha and ferritin may contribute to the insulin resistance found in HCV positive Egyptian patients. Curr Med Res Opin 21:527-534, 2005
10. Masini M, Campani D, Boggi U, Menicagli M, Funel N, Pollera M, Lupi R, Del Guerra S, Bugliani M, Torri S, Del Prato S, Mosca F, Filipponi F, Marchetti P: Hepatitis C virus infection and human pancreatic β-cell dysfunction. Diabetes Care 28:940-941, 2005
11. Narita R, Abe S, Kihara Y, Akiyama T, Tabarau A, Otsuki M: Insulin resistance and insulin secretion in chronic hepatitis C virus infection. J Hepatol 41:132-138, 2004
12. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, Phillips JM, Portmann BG, Poulsen H, Scheuer PJ, Schmid M, Thaler H: Histological grading and staging of chronic hepatitis. J Hepatol 22:696-699, 1995
13. Imano E, Kanda T, Ishigami Y, Kubota M, Ikeda M, Matsuhisa M, Kawamori R, Yamasaki Y: Interferon induces insulin resistance in patients with chronic active hepatitis C. J Hepatol 28:189-193, 1998
14. Konrad T, Zeuzem S, Vicini P, Toffolo G, Briem D, Lormann J, Herrmann G, Berger A, Kusterer K, Teuber G, Cobelli C, Usadel KH: Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-α. Eur J Clin Invest 30:111-121, 2000
15. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW: A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 341:718-724, 1999
16. Díez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D: Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 54:1-8, 1995
17. Matthews DR, Hosker JP, Rudenki AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
18. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Järvinen H, Van Haeften T, Renn W, Gerich J: Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23:295-301, 2000
19. Iwasaki Y, Ohkubo A, Kajinuma H, Akanuma Y, Kosaka K: Degradation and secretion of insulin in hepatic cirrhosis. J Clin Endocrinol Metab 47:774-779, 1978
20. Pimenta WP, Santos ML, Cruz NS, Aragon FF, Padovani CR, Gerich JE: Insulin secretion, insulin sensitivity, and hepatic insulin extraction in first-degree relatives of type 2 diabetic patients. Braz J Med Biol Res 36:301-308, 2003
21. Fernández-Real JM, Ricart W: Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftiness. Diabetologia 42:1367-1374, 1999
22. Fernandez-Real JM, Broch M, Ricart W, Casamitjana R, Gutierrez C, Vendrell J, Richart C: Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes 47:1757-1762, 1998
23. Pickup JC, Chusney GD, Thomas SM, Burt D: Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 67:291-300, 2000
24. Fernández-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, Ricart W: Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 86:1154-1159, 2001
25. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334, 2001
26. Malaguarnera M, Di Fazio I, Romeo MA, Restuccia S, Laurino A, Trovato BA: Elevation of interleukin 6 levels in patients with chronic hepatitis due to hepatitis C virus. J Gastroenterol 32:211-215, 1997
27. Kallinowski B, Haseroth K, Marinos G, Hanck C, Stremmel W, Theilmann L, Singer MV, Rossol S: Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis Cvirus (HCV) infection. Clin Exp Immunol 111:269-277, 1998
28. Zylberberg H, Rimaniol AC, Pol S, Masson A, De Groote D, Berthelot P, Bach JF, Brechot C, Zavala F: Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 30:185-191, 1999
29. Itoh Y, Okanoue T, Ohnishi N, Sakamoto M, Nishioji K, Nakagawa Y, Minami M, Murakami Y, Kashima K: Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection. Am J Gastroenterol 94:1332-1340, 1999
30. Cotler SJ, Reddy KR, McCone J, Wolfe DL, Liu A, Craft TR, Ferris MW, Conrad AJ, Albrecht J, Morrissey M, Ganger DR, Rosenblate H, Blatt LM, Jensen DM, Taylor MW: An analysis of acute changes in interleukin-6 levels after treatment of hepatic C with consensus interferon. J Interferon Cytokine Res 21:1011-1019, 2001
31. Neuman MG, Benhamou JP, Bourliere M, Ibrahim A, Malkiewicz I, Asselah T, Martinot-Peignoux M, Shear NH, Katz GG, Akremi R, Benali S, Boyer N, Lecomte L, Le Breton V, Le Guludec G, Marcellin P: Serum tumour necrosis factor-α and transforming growth factor-β levels in chronic hepatitis C patients are immunomodulated by therapy. Cytokine 17:108-117, 2002
32. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N: Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 38:1384-1392, 2003
33. Greenberg AS, McDaniel ML: Identifying the links between obesity, insulin resistance and β-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 32 (Suppl. 3):24-34, 2002
34. Ruan H, Lodish HF: Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-α. Cytokine Growth Factor Rev 14:447- 455, 2003
35. Nocente R, Ceccanti M, Bertazzoni G, Cammarota G, Silveri NG, Gasbarrini G: HCV infection and extrahepatic manifestations (Review). Hepatogastroenterology 50:1149-1154, 2003
36. Honeyman MC, Stone NL, Harrison LC: T-cell epitopes in type 1 diabetes autoantigen tyrosine phosphatase IA2: potential for mimicry with rotavirus and other environmental agents. Mol Med 4:231-239, 1998
37. Piquer S, Hernández C, Enríquez J, Ross A, Esteban JI, Genesca J, Bonifacio E, Puig-Domingo M, Simó R: Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: effect of treatment with interferon. J Lab Clin Med 137:38-42, 2001
38. Yoon JW, Austin M, Onodera T, Notkins AL: Virus-induced diabetes mellitus: isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med 300: 1173-1179, 1979
39. Helmke K, Otten A, Willems W: Islet cell antibodies in children with mumps infection (Letter). Lancet 2:211-212, 1980
40. Pak CY, Eun HM, McArthur RG, Yoon JW: Association of cytomegalovirus infection with autoimmune type 1 diabetes. Lancet 2:1-4, 1988